NCT06456528 QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
| NCT ID | NCT06456528 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Condition | Cancer Treatment-Induced Thrombocytopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 235 participants |
| Start Date | 2024-10-22 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 235 participants in total. It began in 2024-10-22 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Men and women, 18-75 years of age; * Histopathological or cytological examination confirmed cancer , chemotherapy cycle of 21 days; * Participant experienced thrombocytopenia and chemotherapy delay; * ECOG performance status 0-1; * The estimated survival time at screening is ≥12 weeks, and the current chemotherapy regimen can be accepted for at least 2 cycles. Exclusion Criteria: * Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia; * Participant has serious bleeding symptoms; * History of allergy to the study drug; * Patients with hepatitis C antibody positive and detection of HCV-RNA exceeding the upper limit, patients with hepatitis B surface antigen positive and detection of HBV-DNA exceeding the upper limit, patients with severe cirrhosis, HIV antibody positive and syphilis antibody positive; * Pregnant or lactating women; * Participant has received any experimental therapy within 28 days prior to screening * Other conditions that may affect participant's safety or trial evaluations per investigator's discretion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06456528 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cancer Treatment-Induced Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06456528 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06456528 currently recruiting?
Yes, NCT06456528 is actively recruiting participants. Contact the research team at majun0322@126.com for enrollment information.
Where is the NCT06456528 trial being conducted?
This trial is being conducted at Harbin, China, Nanjing, China.
Who is sponsoring the NCT06456528 clinical trial?
NCT06456528 is sponsored by Qilu Pharmaceutical Co., Ltd.. The trial plans to enroll 235 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.